167 related articles for article (PubMed ID: 30279820)
1. Successful treatment of a massive pulmonary embolism using rivaroxaban in a patient with antithrombin III deficiency.
Yamaguchi J; Hara N; Yamaguchi T; Nagata Y; Nozato T; Miyamoto T
J Cardiol Cases; 2017 Nov; 16(5):144-147. PubMed ID: 30279820
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency.
Minami K; Kumagai K; Sugai Y; Nakamura K; Naito S; Oshima S
Intern Med; 2018 Jul; 57(14):2025-2028. PubMed ID: 29526957
[TBL] [Abstract][Full Text] [Related]
3. The Successful Prevention of Thromboembolism Using Rivaroxaban in a Patient with Antithrombin Deficiency during the Perioperative Period.
Kawai H; Matsushita H; Kawada H; Ogawa Y; Ando K
Intern Med; 2017 Sep; 56(17):2339-2342. PubMed ID: 28794370
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment with rivaroxaban of an extended deep vein thrombosis complicated by pulmonary embolism in a patient with familial antithrombin III deficiency: a case report.
Appignani M; Sciartilli A; Caputo M; Di Girolamo E
Eur Heart J Case Rep; 2020 Feb; 4(1):1-5. PubMed ID: 32128502
[TBL] [Abstract][Full Text] [Related]
5. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Robertson L; Kesteven P; McCaslin JE
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010957. PubMed ID: 26636644
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism.
Chen T; Lam S
Cardiol Rev; 2009; 17(4):192-7. PubMed ID: 19525681
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: A pilot study.
Zhang L; Zhang H; Zhang J; Tian H; Liang J; Liu Z
Exp Ther Med; 2018 Jan; 15(1):739-744. PubMed ID: 29399079
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment with rivaroxaban for an acute pulmonary thromboembolism in a patient with primary antiphospholipid antibody syndrome.
Okamura G; Kawano H; Yoshida N; Koga S; Ikeda S; Ichinose K; Maemura K
J Cardiol Cases; 2020 Feb; 21(2):79-81. PubMed ID: 32042361
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
Rank CU; Lynggaard LS; Als-Nielsen B; Stock W; Toft N; Nielsen OJ; Frandsen TL; Tuckuviene R; Schmiegelow K
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013399. PubMed ID: 33038027
[TBL] [Abstract][Full Text] [Related]
11. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
[TBL] [Abstract][Full Text] [Related]
12. The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
Akwaa F; Spyropoulos AC
Curr Med Res Opin; 2014 Nov; 30(11):2179-90. PubMed ID: 25105309
[TBL] [Abstract][Full Text] [Related]
13. The Use of Rivaroxaban for Unprovoked Pulmonary Embolism in the Setting of Antithrombin Deficiency.
Gryn OJ; Nguyen T; Frankova D
Cureus; 2020 Jun; 12(6):e8560. PubMed ID: 32670697
[TBL] [Abstract][Full Text] [Related]
14. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
[TBL] [Abstract][Full Text] [Related]
15. Practical management of rivaroxaban for the treatment of venous thromboembolism.
Imberti D; Benedetti R
Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Venous Thromboembolism With New Anticoagulant Agents.
Becattini C; Agnelli G
J Am Coll Cardiol; 2016 Apr; 67(16):1941-55. PubMed ID: 27102510
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism.
Harder S
Thromb J; 2014; 12():22. PubMed ID: 25698904
[TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.
Arcelus JI; Domènech P; Fernández-Capitan Mdel C; Guijarro R; Jiménez D; Jiménez S; Lozano FS; Monreal M; Nieto JA; Páramo JA
Clin Appl Thromb Hemost; 2015 May; 21(4):297-308. PubMed ID: 25504999
[TBL] [Abstract][Full Text] [Related]
19. Apixaban therapy in a pregnant woman with heparin-induced thrombocytopenia and venous thromboembolic events caused by congenital antithrombin deficiency: A case report.
Komori M; Hayata E; Nakata M; Yuzawa H; Oji A; Morita M
Case Rep Womens Health; 2020 Jul; 27():e00200. PubMed ID: 32300539
[TBL] [Abstract][Full Text] [Related]
20. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
